Neuroprotection trials in Parkinson's disease: Systematic review
Identifieur interne : 000A19 ( Main/Exploration ); précédent : 000A18; suivant : 000A20Neuroprotection trials in Parkinson's disease: Systematic review
Auteurs : Robert G. Hart [États-Unis] ; Lesly A. Pearce [États-Unis] ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-04-15.
English descriptors
Abstract
Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double‐blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO‐B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow‐up averaged <16 months in all but two trials. Detailed randomization methods and success of double‐blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteria for futility. Neuroprotection trials have involved relatively uniform groups of participants early in the clinical disease course, with outcomes weighted heavily toward motor deterioration. Future trials should include participants with wider ranges of disease stages and assess broader neurological outcomes. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22432
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotection trials in Parkinson's disease: Systematic review</title><author><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name></author><author><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name></author><author><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name></author><author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name></author><author><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8497F5F14173A746A749AFCA36A04C039BDD0BE0</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22432</idno><idno type="url">https://api.istex.fr/document/8497F5F14173A746A749AFCA36A04C039BDD0BE0/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000055</idno><idno type="wicri:Area/Main/Curation">000044</idno><idno type="wicri:Area/Main/Exploration">000A19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroprotection trials in Parkinson's disease: Systematic review</title><author><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Texas Health Science Center, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Minot, North Dakota</wicri:regionArea><placeName><region type="state">Dakota du Nord</region></placeName></affiliation></author><author><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Texas Health Science Center, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15">2009-04-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="647">647</biblScope><biblScope unit="page" to="654">654</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8497F5F14173A746A749AFCA36A04C039BDD0BE0</idno><idno type="DOI">10.1002/mds.22432</idno><idno type="ArticleID">MDS22432</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical trial</term><term>disease‐modifying</term><term>neuroprotection</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double‐blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO‐B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow‐up averaged <16 months in all but two trials. Detailed randomization methods and success of double‐blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteria for futility. Neuroprotection trials have involved relatively uniform groups of participants early in the clinical disease course, with outcomes weighted heavily toward motor deterioration. Future trials should include participants with wider ranges of disease stages and assess broader neurological outcomes. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Dakota du Nord</li><li>Maryland</li><li>Texas</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name></region><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8497F5F14173A746A749AFCA36A04C039BDD0BE0
|texte= Neuroprotection trials in Parkinson's disease: Systematic review
}}
| This area was generated with Dilib version V0.6.23. |  |